BPH isn't caused by testosterone directly, but by a specific hormone the prostate converts it into — and that distinction is exactly why the two main medication classes for it work in genuinely different ways.
Benign prostatic hyperplasia — non-cancerous prostate enlargement — is extremely common as men age, and understanding the specific mechanism behind it explains both why it causes the symptoms it does and why the two main medication classes used to treat it work in such different ways.
What Actually Happens to the Prostate With Age
Prostate tissue growth with age is hormonally driven, but not directly by testosterone itself — within the prostate, an enzyme converts testosterone into dihydrotestosterone (DHT), a considerably more potent hormone at the receptors responsible for prostate tissue growth. Over decades, this ongoing conversion process contributes to the gradual tissue growth that defines BPH, which is precisely why one of the main medication classes for this condition, discussed below, targets this specific conversion step directly.
Why an Enlarged Prostate Causes Urinary Symptoms
The prostate sits directly around the urethra, the channel urine passes through on its way out of the bladder. As prostate tissue grows, it physically narrows this channel, and increased smooth muscle tension in the surrounding area can compound this narrowing dynamically. Together, these two factors — physical compression and muscle tension — explain the combination of urinary symptoms typically associated with BPH, including a weaker stream, difficulty starting urination, and a frequent urge to urinate.
How Symptom Severity Is Actually Scored
Rather than relying on a vague sense of "mild" or "severe," a structured, validated symptom scoring tool (the International Prostate Symptom Score, or IPSS, is the most widely used) is commonly used clinically to quantify symptom severity and, importantly, to track how well a given treatment is working over time by comparing scores before and after starting it.
Complications of Leaving BPH Untreated
- Acute urinary retention — a sudden inability to urinate at all — is an uncommon but genuine medical urgency that can occur with significant, untreated BPH.
- Chronic bladder muscle changes, resulting from the bladder working harder against a narrowed outlet over an extended period, can affect bladder function over time even after the obstruction itself is later treated.
- Increased urinary tract infection risk, related to incomplete bladder emptying that allows bacteria more opportunity to establish an infection.
- Kidney function effects, in more severe and prolonged cases of obstruction, representing a less common but more serious potential complication of long-neglected symptoms.
Alpha-Blockers: Fast Relief Through Muscle Relaxation
Alpha-blockers work by relaxing smooth muscle specifically in the prostate and bladder neck area, reducing the dynamic component of urinary obstruction described above. This tends to provide relatively fast symptom relief — often within days to a couple of weeks — though it doesn't reduce the size of the prostate tissue itself, since it addresses the muscle tension component rather than the tissue growth.
5-Alpha-Reductase Inhibitors: A Slower Mechanism That Shrinks the Prostate Itself
This second medication class works through an entirely different, complementary mechanism: by blocking the enzyme that converts testosterone into DHT within the prostate, it gradually reduces the hormonal signal driving tissue growth, leading to an actual reduction in prostate size over a period of months. Because this effect takes considerably longer to develop than an alpha-blocker's muscle-relaxing effect, the two classes are frequently combined — the alpha-blocker providing faster symptom relief while the 5-alpha-reductase inhibitor works on gradually shrinking the underlying tissue over the longer term.
Quick Comparison
| Medication class | Mechanism | Onset | Shrinks the prostate? |
|---|---|---|---|
| Alpha-blockers | Relaxes prostate and bladder-neck muscle | Days to weeks | No |
| 5-alpha-reductase inhibitors | Blocks the hormone that drives tissue growth | Months | Yes |
When Medication Isn't Enough: How Treatment Options Have Expanded
Important
For BPH that doesn't respond adequately to medication, or for larger prostates causing more significant symptoms, treatment options have expanded considerably beyond traditional surgery in recent years, with several newer minimally invasive procedural options now available. The right choice among these depends on prostate size, symptom severity, and individual patient preference, and is a conversation best had directly with a urologist familiar with the specific details of a given case.
